pharmaphorum Podcast

Purespring Therapeutics is a precision nephrology company pioneering first-in-class, targeted genetic therapies designed to preserve kidney function.

In a new pharmaphorum podcast, web editor Nicole Raleigh speaks with Haseeb Ahmad, CEO of Purespring, who discusses transforming the treatment of kidney disease, an area of enormous unmet need, with more than 840 million people worldwide living with chronic kidney disease.

Indeed, Pur...

Europe's biotech sector is facing an innovation cliff, with fewer clinical starts, tighter capital, and increasing development complexity.

In a new pharmaphorum podcast, web editor Nicole Raleigh caught up with Paul Bridges, president, consulting, at Parexel, and Charlotte Moser, Parexel’s chief medical officer, following BIO-Europe Spring in Lisbon, Portugal.

The conversation touches upon regulatory strategy and evolving pol...

Cutaneous T-cell lymphoma (or CTCL) is a rare form of non-Hodgkin lymphoma that begins in T lymphocytes, a kind of white blood cell that plays a crucial role in the immune system. And Citius Oncology is focused on developing and commercialising a targeted immune therapy for the initial indication of the treatment of persistent or recurrent CTCL.

In a new pharmaphorum podcast, web editor Nicole Raleigh spoke with Leonard Mazur, CEO ...

The radiopharmaceutical sector is in the midst of a transformative year in 2026, with significant developments and challenges, including policy and reimbursement, increasing demand and growth within precision oncology and molecular imaging, and the need for specialised CDMOs when it comes to the intricate nature of radiopharmaceutical manufacturing.

In a new pharmaphorum podcast, web editor Nicole Raleigh speaks with Dr Andrew Cave...

2026 is the year of a major wave of pharmaceutical patent expirations, with numerous blockbuster drugs – spanning diabetes, immunology, cardiovascular, oncology, and other therapeutic areas – on the verge of losing market exclusivity.

In a new pharmaphorum podcast, web editor Nicole Raleigh speaks with Rebecca Guntern, chief commercial officer at Sandoz, for a conversation on the ‘golden decade’ for generics...

In a new pharmaphorum podcast, web editor Nicole Raleigh spoke with Lee-Ann Farrell, Head of National Programmes at Johnson & Johnson, about what delivery will look like in practice when it comes to the National Cancer Plan, the 10-Year Health Plan, and the Life Sciences Sector Plan.

The conversation ranges what comes next following the clear policy direction of the Plans, including how the system can move from ambition to impl...

In a new pharmaphorum podcast, web editor Nicole Raleigh speaks with Kris Kaneta, chief product officer at Norstella, which is helping life sciences companies speed up development with instant strategy recommendations.

Kaneta discusses AI in drug trials and commercialisation and just what’s possible when clinical AI has access to a data set robust enough to allow it to make real strategic recommendations.

Kaneta also tou...

In a new pharmaphorum podcast, web editor Nicole Raleigh speaks with Dr Ramy Younes, Corporate Vice President, Global Head of Clinical Development, CardioRenalMetabolism, at Boehringer Ingelheim.

The conversation explores the crisis beyond obesity that many clinicians and health systems are now grappling with: that obesity can’t be treated as a short-term, weight-loss lifestyle issue. Rather, it needs to be managed as a compl...

In a new pharmaphorum podcast, web editor Nicole Raleigh sat down with Dr Cedrik Britten, chief medical officer at Immatics, to discuss novel PRAME-directed T-cell immunotherapies.

Targeting PRAME unlocks new treatment options for a broad patient population with significant unmet medical need. And to do so safely and effectively requires deep expertise in immunology, drug development, and beyond.

Britten explains how finding the ri...

Longevity and healthspan have emerged rapidly as an increasingly serious category of healthcare study and investment. But there are a lot of ideas inside the industry and out about exactly what the goal is. Is it about extending lifespans as much as possible? Are we trying to live forever? Or do we just want to experience less physical and cognitive decline as we age?

In today’s episode of the pharmaphorum podcast, host Jonah...

Today, the life sciences sector is prioritising recruitment of leaders who can scale efficiently in capital-constrained environments, as well as focusing on hybrid operator-strategists who can integrate AI into R&D, clinical, and commercial workflows.

In a new pharmaphorum podcast, web editor Nicole Raleigh spoke with John Holodnak, co-founder of Occam, about how AI is beginning to reshape career paths across life sciences.

Hol...

Pharma and tech companies are working more closely together than ever. As proven by the news of Merck and NVidia’s new partnership, for example. But while the idea of using AI for drug discovery has been around for a while now, patient access has an awfully long way to catch up to the promise of these new therapies.

In a new pharmaphorum podcast, web editor Nicole Raleigh speaks with Dean Erhardt, founder of D2 Solutions, an ...

Despite billions spent on new technology and improving data analytics, companies continue to struggle with commercial launch success, with around 35% of launches missing expectations since 2012.

Why is launch underperformance such a big problem, and why isn’t technology alone offering a sufficient solution? In a special episode of the pharmaphorum podcast, sponsored by Axtria, we spoke with Amanjeet Singh Saluja, a Principal ...

Here at pharmaphorum we tend to focus on the latest developments in the pharmaceutical space. And to be fair, that’s quite a lot to keep us busy. But the history of pharma is full of incredible stories that might just be new to a lot of people, even those inside the industry.

On today’s episode of the pharmaphorum podcast, host Jonah Comstock speaks with Thomas Goetz, former executive editor of Wired; co-founder of Iodi...

In a new episode of the pharmaphorum podcast, web editor Nicole Raleigh spoke with Lance Baldo, CEO of Beacon Therapeutics, a clinical-stage biotechnology company harnessing the transformative power of gene therapy to deliver meaningful outcomes for severe ocular diseases.

Baldo discusses the ocular disease landscape, as well as Beacon’s work targeting X-linked retinitis pigmentosa (XLRP) and geographic atrophy (GA), and what...

In a new episode of the pharmaphorum podcast, recorded at BIO-Europe Spring in Lisbon, Portugal, web editor Nicole Raleigh spoke with Kashif Sadiq, founder and CEO of DenovAI Biotech, a company that believes humanity is on the cusp of a protein design revolution that stands to transform both human health and the world around us.

Sadiq discusses the company's springboard from AION Labs - with a first-of-its-kind alliance of AstraZen...

At BIO-Europe Spring 2026 in Lisbon, Portugal, web editor Nicole Raleigh spoke with Dr Olga Nissan, vice president of business development at Evogene, a computational chemistry company, specialising in the generative design of small molecules for the pharmaceutical and agricultural industries.

Nissan discusses recent developments at Evogene, including its extended collaboration with Google Cloud to develop and integrate AI agents i...

In a new pharmaphorum podcast, web editor Nicole Raleigh was joined by Rob DiCicco, vice president of portfolio management at Transcelerate Biopharma Inc, for a conversation on the barriers and the breakthroughs in making AI work in drug development and clinical trials.

DiCicco discusses why AI adoption in clinical trials is so different from preclinical research and development, as well as how synthetic control arms and in silico ...

Genetic diseases are notoriously challenging to treat, especially when each condition requires a tailored approach. With over 10,000 known genetic disorders, developing individual therapies for each one has been an immense hurdle, particularly for rare diseases affecting small patient populations. But what if there was a way to address multiple conditions simultaneously, using a single, universal approach?

In today’s episode ...